DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ. et al.
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Blood 2016;
128: 1562-6
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.